1. Scrip
  2. >>Focus On Asia

15 Chinese Formulation Makers Receive Export Licenses From 29 Nations

Fifteen Chinese formulation producers have recently acquired pharma quality certificates from 29 overseas countries including the U.S., Japan, and 27 European countries.

Fifteen Chinese formulation producers have recently acquired pharma quality certificates from 29 overseas countries including the U.S., Japan, and 27 European countries. The certified companies include Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Zhejiang Huahai Pharmaceuticals Co. Ltd., Lijian Pharmacy Co. Ltd., Zhejiang Jingxin Pharmaceutical Co. Ltd., CSPC Ouyi Pharmaceutical Co. Ltd., Huayi Pharmaceutical (Anhui) Co. Ltd., Shenzhen Gosun Pharmaceutical Co. Ltd., Shenzhen Zhijun Pharmaceutical Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Hangzhou Minsheng Pharmaceutical Group Co. Ltd., Zhejiang Jinhua CONBA Bio-pharm Co. Ltd., and Youcare Pharmaceutical Group Co. Ltd. China aims to have more than 80 drug companies obtain certification from overseas nations or the World Health Organization by 2016. (Click Here For More - Chinese Language

)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 
• By Andrew McConaghie

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 
• By Dexter Jie Yan

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.

US Tariff Overhang Weighs on Chinese API Exports

 
• By Dexter Jie Yan

Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.

More from Focus On Asia